Excited to share an ASHP CE podcast that Dr. Natalie Rodriguez, PharmD, BCACP, CDCES, and I recorded! 🎙️ GLP Practice Insights: New Agents, New Data, and New Access Opportunities In this episode, we discuss emerging GLP therapies, the latest clinical evidence, and practical considerations for patient access. Listen below 👇

📊 Summer is here and so is the 4th episode of Market Signal A mid-year check-in on the state of the life science sector, courtesy of two seasoned and sharp voices 🌞 Cecilia Hallström zooms out to the big picture this time: global capital flows and what they mean for Nordic life science. First up: Jonathan P. Gertler, MD, Co-founder & CEO of Back Bay Life Science Advisors, on the state of global biotech financing, China's rise as a dealmaking powerhouse, and what Nordic companies need to get right when courting US capital. Then: Adam Kostyal, President of Nasdaq Stockholm, on whether the Nordic listings market is genuinely bouncing back, what it takes to go public today, and what Europe needs to do to compete on the global stage. Watch the full episode here: https://lnkd.in/dM49wVjZ

Global capital flows, evolving financing markets, and cross-border dealmaking continue to shape opportunities across life sciences.    Our Co-founder & CEO, Jonathan P. Gertler, MD, joined BioStock’s Market Signal to discuss the current biotech financing environment, China’s growing role in global dealmaking, and what Nordic companies should consider when engaging U.S. investors.    Thank you to Cecilia Hallström, PhD and BioStock - Connecting Innovation and Capital for the conversation.    Watch the full episode below ⬇️

Australia was one of the first countries in the world to introduce HTA. In some ways, that's a strength. In others, it means the system has been running on assumptions that date back to the 1980s.    This week I joined Grace Hampson and Martina Garau on A Dose of Economics to talk about HTA reform — what's driving it globally, what Australia's recent methods review got right, and what still needs to happen before Australian patients can reliably access the medicines they need.    See and listen to the podcast here: https://lnkd.in/gQaGWnPK

Recorded in 2025, this conversation captured the IVDR at a turning point. Today, it feels more timely than ever. In this podcast episode of Greiner Bio-One Talks, Prof. Dr. Christa Cobbaert shares a perspective that now reads almost like a preview of today’s IVDR debate: how a regulation designed to protect patients also created major implementation challenges for laboratories and manufacturers. In our podcast conversation, Christa speaks openly about: 💡 why the IVDR emerged from earlier legislation that was considered too soft 💡 how the new framework became overly stringent for many labs and manufacturers 💡 why SMEs, specialty testing, and rare disease diagnostics were placed under particular pressure 💡 which regulatory pathways are still missing for breakthrough innovation 💡 how EFLM, BioMed Alliance, and MedTech Europe joined forces to push for more balanced revision With the amendment proposal now on the table, the relevance of this 2025 conversation is hard to miss. What was discussed then, is now likely to get reflected in the regulation. Real-world insight, practical takeaways, and an important reminder: regulation needs to protect patients without slowing the innovation they depend on. At Greiner Bio-One, we believe these are conversations worth continuing across the diagnostic community. Watch the episode highlights and share your perspective with us!

Early narratives in #biopharma matter because they shape how your science is understood, believed, and ultimately supported; long before the full data is available. Getting them right is far from easy. In our latest IDEA Pharma | From R&D to RxD Collider podcast, Susan Wood and Rick Ritacco explore the challenges and opportunities of shaping early-phase narratives that are both compelling and differentiated. A key question they tackle: how do you effectively communicate the science while conveying real potential? Listen or reach out if you're building a story around innovation or translating complex ideas into impact. Listen here: https://lnkd.in/e6wmWSKe Full video: https://lnkd.in/eSfPB-q2

Are you making your biotech's science too complicated for investors and physicians? 🧬 In our latest IDEA Collider episode, host Rick Ritacco speaks with Susan Wood, senior positioning expert at IDEA Pharma | From R&D to RxD, about crafting powerful early narratives. Learn how to simplify complex mechanisms without "dumbing them down" and why team conviction often matters more than absolute narrative precision. Listen now! 🎧👇 https://lnkd.in/edrzFGgZ

I had a great time discussing the challenges and opportunities on early phase narrative with Rick Ritacco in one of the IDEA Collider podcasts. Listen to the audio below (or I would highly recommend the video version on YouTube https://lnkd.in/e6u8UHcW. It was insightful for me to consider (in real time) how my experience in and out of pharma has shaped the way I communicate science and potential

Thank you to the ERAMET Project for featuring Donato Bonifazi, Chair of the TEDDY Network, in this new episode of Meet the Consortium. In this episode highlights how TEDDY‘s collaboration within ERAMET is contributing to more efficient and evidence-informed medical product development for small patient populations including work on clinical trial optimisation, paediatric extrapolation, and improved dose prediction approaches. These efforts reflect the importance of advancing methodologies that support better evidence generation and more effective development pathways. 🎥 Watch the full episode: https://lnkd.in/eg5AyAYe 📰 Read more about the project: https://lnkd.in/e5c-HGuh #TEDDYNetwork #ERAMET #ClinicalResearch #Paediatrics #MedicineDevelopment #RareDiseases #Childrenfirst

In the latest episode of the Market Access Podcast from our friends at MArS Market Access & Pricing Strategy GmbH, the discussion focuses on the implications of the EU JCA. In the conversation between Stefan Dr. Walzer and Alexander Katz (EUCOPE), they get into the pressures Most Favored Nation is putting on pricing in Europe and why EU health data comparator selection is set to play a key role in pricing and reimbursement discussions. We really do recommend this podcast for anyone working in the market access space as well as those in pharma and biotech looking at their global launch strategy. #MarketAccess #Podcast #EUJCA #JCA #MFN #Pricing #Reimbursement #Launch